Mitra Abbasifard1,2, Tahmineh Kandelouei3, Saeed Aslani4, Bahman Razi5, Danyal Imani6, Mahdieh Fasihi6, F G Cicero7, Amirhossein Sahebkar8,9,10,11,12,13. 1. Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. 2. Department of Internal Medicine, School of Medicine, Ali Ibn Abi Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. 3. Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Pathobiology and Laboratory Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. 6. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Enghelab Av., 14117, Tehran, Iran. 7. IRCCS Policlinico S. Orsola-Malpighi, Hypertension and Cardiovascular Risk Factors Research Unit, University of Bologna, Bologna, Italy. 8. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 9. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 10. Department of Biotechnology and Nanotechnology, Faculty of Medicine, The University of Western Australia, Perth, Australia. sahebkara@mums.ac.ir. 11. School of Medicine, The University of Western Australia, Perth, Australia. sahebkara@mums.ac.ir. 12. Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 13. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, P.O. Box: 91779-48564, Mashhad, Iran. sahebkara@mums.ac.ir.
Abstract
BACKGROUND: The anti-inflammatory properties of statins have been suggested by several researches. However, clinical trials have reported incongruous findings regarding the effect of statins on the levels of inflammatory markers other than high-sensitive C-reactive protein. Therefore, a systematic review and meta-analysis of randomized clinical trials were conducted to illuminate the effect of statins on serum levels of TNF-α, MCP-1, VCAM1, and IL-6 in patients with cardiovascular diseases (CVDs). METHODS: To find eligible studies, a systematic literature search of the main databases were conducted up to July 2021. The calculation of the effect sizes was conducted by standardized mean difference (SMD) and 95% confidence intervals (CI). RESULTS: The pooled analyses revealed that statins significantly reduced the TNF-α concentration (SMD = - 0.99 pg/mL; 95% CI - 1.43 to - 0.55 pg/mL; P < 0.001). Regarding dosage, high intensity (SMD = - 0.65 pg/mL; 95% CI - 1.19 to - 0.10, P = 0.02) and moderate/low (SMD = - 1.16 pg/mL; 95% CI - 1.84 to - 0.47, P = 0.001) intensity statins significantly decreased TNF-α levels. Moderate/low intensity statins administration in < 10 weeks treatment duration decreased serum level of TNF-α (SMD = - 0.91 pg/mL; 95% CI - 1.38 to - 0.44, P < 0.001). Lipophilic statins with high intensity dosage significantly decreased level of TNF-α (SMD = - 0.73 pg/mL; 95% CI - 1.43 to - 0.03, P = 0.04). Statins did not change serum levels of MCP-1, VCAM1, and IL-6 in CVD patients. CONCLUSIONS: The analyses indicated that statins have beneficial effects in decreasing serum levels of TNF-α in patients with CVDs.
BACKGROUND: The anti-inflammatory properties of statins have been suggested by several researches. However, clinical trials have reported incongruous findings regarding the effect of statins on the levels of inflammatory markers other than high-sensitive C-reactive protein. Therefore, a systematic review and meta-analysis of randomized clinical trials were conducted to illuminate the effect of statins on serum levels of TNF-α, MCP-1, VCAM1, and IL-6 in patients with cardiovascular diseases (CVDs). METHODS: To find eligible studies, a systematic literature search of the main databases were conducted up to July 2021. The calculation of the effect sizes was conducted by standardized mean difference (SMD) and 95% confidence intervals (CI). RESULTS: The pooled analyses revealed that statins significantly reduced the TNF-α concentration (SMD = - 0.99 pg/mL; 95% CI - 1.43 to - 0.55 pg/mL; P < 0.001). Regarding dosage, high intensity (SMD = - 0.65 pg/mL; 95% CI - 1.19 to - 0.10, P = 0.02) and moderate/low (SMD = - 1.16 pg/mL; 95% CI - 1.84 to - 0.47, P = 0.001) intensity statins significantly decreased TNF-α levels. Moderate/low intensity statins administration in < 10 weeks treatment duration decreased serum level of TNF-α (SMD = - 0.91 pg/mL; 95% CI - 1.38 to - 0.44, P < 0.001). Lipophilic statins with high intensity dosage significantly decreased level of TNF-α (SMD = - 0.73 pg/mL; 95% CI - 1.43 to - 0.03, P = 0.04). Statins did not change serum levels of MCP-1, VCAM1, and IL-6 in CVD patients. CONCLUSIONS: The analyses indicated that statins have beneficial effects in decreasing serum levels of TNF-α in patients with CVDs.
Authors: Rabih R Azar; Georges Badaoui; Antoine Sarkis; Roland Kassab; Elie Salamé; Samira Klaymé; Roger Naman; Mirna Germanos Journal: Am J Cardiol Date: 2005-01-15 Impact factor: 2.778
Authors: Afsane Bahrami; Negin Parsamanesh; Stephen L Atkin; Maciej Banach; Amirhossein Sahebkar Journal: Pharmacol Res Date: 2018-08-16 Impact factor: 7.658
Authors: Esam Abulhul; Kenneth McDonald; Ramon Martos; Dermot Phelan; J Paul Spiers; Martina Hennessy; John Baugh; Chris Watson; Christina O'Loughlin; Mark Ledwidge Journal: Clin Ther Date: 2011-12-09 Impact factor: 3.393
Authors: Ethan M Balk; Joseph Lau; Leonidas C Goudas; Harmon S Jordan; Bruce Kupelnick; Linda U Kim; Richard H Karas Journal: Ann Intern Med Date: 2003-10-21 Impact factor: 25.391